Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 372 for “"gemcitabine"”.

  1. Gemcitabine pharmacogenetics and mechanisms involved in synergistic interaction of gemcitabine in combination with platinum drugs

    Gemcitabine (GEM) is a nucleoside analogue, which is commonly used to treat solid tumours. The activity of GEM is correlated with intracellular accumulation of its active metabolite, gemcitabine-triphosphate (GEM-TP). This thesis aims to explore the effect on GEM accumulation of: the genetics of …

    unsw Repository record for Gemcitabine pharmacogenetics and mechanisms involved in synergistic interaction of gemcitabine in combination with platinum drugs (opens in a new tab)

  2. Synthesis of gemcitabine and it's tetrafluorinated analogues

    … 2-deoxy-2,2-difluorocytidine nucleoside analogue gemcitabine has been achieved. Starting from the known 3,5-O-dibenzoyl-2- deoxy-2,2-difluororibose, the nucleobase moiety is constructed in a linear fashion, using amino- or urea glycosylation methodology. This methodology has also been employed to …

    soton Download PDF for Synthesis of gemcitabine and it's tetrafluorinated analogues (opens in a new tab)

  3. Delivery of Gemcitabine, Stearoyl Gemcitabine and Paclitaxel Through PLGA Nanoparticles and Its Effect on the Desmoplasia of Pancreatic Cancer Spheroids

    … surrounds the tumor and restricts blood supply. Gemcitabine (GEM) and paclitaxel (PTX) are drugs that are clinically used in the treatment of pancreatic cancer. GEM, however, is rapidly metabolized by cytidine deaminase (CDA) and eliminated from the body, and paclitaxel is a substrate for P- …

    sdstate Repository record for Delivery of Gemcitabine, Stearoyl Gemcitabine and Paclitaxel Through PLGA Nanoparticles and Its Effect on the Desmoplasia of Pancreatic Cancer Spheroids (opens in a new tab)

  4. Gemcitabine Sensitivity on Podocalyxin Knockdown Pancreatic Cell Line SW1990

    … we tested cell survival following treatments of Gemcitabine (GE) in scrambled control and Podocalyxin (PODXL) knockdown pancreatic cancer cell line SW1990. After testing several major chemotherapeutic drugs with MTT cell survival assay, GE, brand name Gemzar, was shown to have a much higher …

    jhu Repository record for Gemcitabine Sensitivity on Podocalyxin Knockdown Pancreatic Cell Line SW1990 (opens in a new tab)

  5. UNDERSTANDING DIFFUSE LARGE B-CELL LYMPHOMA RESISTANCE TOWARDS GEMCITABINE

    … Hence, we aimed to investigate the cause of gemcitabine resistance in DLBCL cell lines and develop a potential therapeutic strategy to overcome the resistance. Firstly, we stratified DLBCL cell lines into gemcitabine sensitive and resistant phenotype through a dose-response assay. Next, we …

    nus Repository record for UNDERSTANDING DIFFUSE LARGE B-CELL LYMPHOMA RESISTANCE TOWARDS GEMCITABINE (opens in a new tab) Download file for UNDERSTANDING DIFFUSE LARGE B-CELL LYMPHOMA RESISTANCE TOWARDS GEMCITABINE (opens in a new tab)

  6. Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer

    Most pancreatic cancer patients receiving gemcitabine chemotherapy eventually develop resistance to gemcitabine. To improve survival and prognosis of pancreatic cancer patients, better understanding the mechanisms of gemcitabine resistance and discovery of new therapeutic targets are required. In …

    iupui Repository record for Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer (opens in a new tab)

  7. Role of ABCC5 in Gemcitabine Resistance in Pancreatic Cancer

    … is one of the most aggressive solid tumours. gemcitabine-based regimens have been used as front-line treatments for patients with advanced pancreatic cancer. gemcitabine may initially show a response, but most often multi-drug resistance (MDR) rapidly develops. Several processes are …

    auckland-tech Repository record for Role of ABCC5 in Gemcitabine Resistance in Pancreatic Cancer (opens in a new tab)

  8. A Systematic Degradation Kinetics Study of Gemcitabine Hydrochloride Injection Solution

    … evaluate the degradation kinetics of gemcitabine hydrochloride injection solution over the pH region 1–12 at 70°C. The degradation kinetics of gemcitabine were determined based on several parameters such as pH, buffer composition, temperature, ionic strength, and drug concentration. A …

    ku Repository record for A Systematic Degradation Kinetics Study of Gemcitabine Hydrochloride Injection Solution (opens in a new tab)

  9. Effects of FUX on Gemcitabine Sensitivity in Lung Cancer Cells

    … treated with the front-line drugs, such as gemcitabine, rapidly develop drug resistance by decreasing cellular accumulation and/or avoiding apoptosis. Fucoxanthin (FUX), extracted from edible seaweed such as Undaria pinnatifida, has recently been reported to inhibit membrane drug efflux …

    auckland-tech Repository record for Effects of FUX on Gemcitabine Sensitivity in Lung Cancer Cells (opens in a new tab)

  10. Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer

    … oxidatively challenged and in combination with gemcitabine by interacting with key sulfhydryl-dependent enzymes involved with gemcitabine metabolism. In vitro anti-tumor activity of imexon and gemcitabine was evaluated in PANC-1, MIA PaCa-2, MutJ, and BxPC-3 human pancreatic cancer cell lines. …

    arizona-thes Repository record for Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer (opens in a new tab)

  11. The DNA Replication Stress Response to Gemcitabine in Pancreatic Cancer Cells

    … on the widely used chemotherapeutic agent gemcitabine in the context of pancreatic cancer. Gemcitabine is a potent inhibitor of DNA replication and is used frequently in combination with other therapies in the clinic, including in pancreatic cancer, but it remains poorly defined how cells …

    toronto-retro Repository record for The DNA Replication Stress Response to Gemcitabine in Pancreatic Cancer Cells (opens in a new tab)

  12. Formulation and evaluation of gemcitabine plus romidepsin + cisplatin combination for controlling tumors

    … study, the safe and efficacious combination of gemcitabine, cisplatin, and romidepsin (Gem plus Rom+Cis) to treat two types of cancer: bladder and breast cancer, was formulated. <em>In vitro </em>data from this study revealed that the combination of Gem plus Rom+Cis synergistically reduced cell …

    utk-theses Repository record for Formulation and evaluation of gemcitabine plus romidepsin + cisplatin combination for controlling tumors (opens in a new tab)

  13. Pharmacometric modeling of anti-cancer agents: application to gemcitabine, PQIP and irinotecan.

    … pharmacometric modeling of irinotecan, PQIP and gemcitabine. Irinotecan is a DNA topoisomerase-I inhibitor used in colorectal and brain tumors. One of our aims was to show that that cranial radiation, delivered during irinotecan administration, can enhance uptake in to cerebral-spinal fluid …

    umn Repository record for Pharmacometric modeling of anti-cancer agents: application to gemcitabine, PQIP and irinotecan. (opens in a new tab)

  14. Development and Characterization of Polymeric Nanoparticulate Delivery System for Hydrophillic Drug: Gemcitabine.

    Gemcitabine is a nucleoside analogue, used in various carcinomas such as non small cell lung cancer, pancreatic cancer, ovarian cancer and breast cancer. The major setbacks to the conventional therapy with gemcitabine include its short half-life and highly hydrophilic nature. The objectives of this …

    creighton Repository record for Development and Characterization of Polymeric Nanoparticulate Delivery System for Hydrophillic Drug: Gemcitabine. (opens in a new tab)

Page 1 of 19